Dysfunctional Uterine Bleeding Management

Diagnostic Approach

• The American College of Family Physicians recommends using the PALM-COEIN classification system to rule out other causes of abnormal uterine bleeding before diagnosing dysfunctional uterine bleeding (DUB) 1, 2
• Adolescence, perimenopause, lactation, pregnancy, hyperandrogenic conditions, hypothalamic dysfunction, hyperprolactinemia, thyroid disease, primary pituitary disease, premature ovarian failure, and iatrogenic causes should be excluded as underlying conditions 1
• Pregnancy should be tested for in all reproductive-age women using β-hCG before proceeding with further evaluation 3
• Hemodynamic stability should be assessed, with urgent evaluation needed if bleeding saturates a large pad/tampon hourly for ≥4 hours 3
• Thyroid-stimulating hormone and prolactin levels should be measured to exclude endocrine causes 1, 3

Imaging and Endometrial Sampling

• Combined transabdominal and transvaginal ultrasound with Doppler is the first-line imaging study to identify structural causes 3
• Saline infusion sonohysterography has 96-100% sensitivity and can distinguish leiomyomas from polyps with 97% accuracy 1, 3
• MRI should be considered when ultrasound incompletely visualizes the uterus or findings are indeterminate 3
• Endometrial biopsy is mandatory in patients with risk factors for endometrial cancer, including age >45 years, postmenopausal status, obesity, diabetes, hypertension, unopposed estrogen exposure, tamoxifen use, and Lynch syndrome 2, 3

Medical Management

• The American College of Family Physicians recommends medical therapy as the first-line treatment for DUB, unless contraindicated or structural pathology requires surgery 1, 2
• Combined oral contraceptives are first-line for most patients with anovulatory DUB, providing cycle regulation and reducing bleeding 1
• Cyclic progestins are appropriate alternatives, especially when estrogen is contraindicated 1
• Progestin-only contraception, including levonorgestrel-releasing intrauterine system, is highly effective for anovulatory DUB 1
• NSAIDs are most effective for ovulatory menorrhagia, reducing bleeding by 20-50% 2
• Tranexamic acid is a non-hormonal alternative that significantly reduces bleeding 2

Surgical Management

• Hysterectomy provides definitive resolution of all symptoms and significantly better health-related quality of life compared to other therapies 2, 3
• Endometrial ablation is a uterus-sparing option for completed childbearing 1
• The least invasive surgical route should be chosen based on uterine size and surgical expertise 2

Referral and Age-Specific Considerations

• Failed medical management, endometrial sampling showing hyperplasia or malignancy, and postmenopausal bleeding with endometrial thickness ≥4 mm are indications for referral 3
• Perimenopausal women have a higher risk for endometrial hyperplasia/cancer and should have a lower threshold for endometrial sampling 2
• Postmenopausal women with any bleeding require evaluation for endometrial cancer 2

Prolactin Testing in the Initial Evaluation of Abnormal Uterine Bleeding

Guideline Recommendations

• The American Family Physician guideline recommends measuring serum prolactin (along with thyroid‑stimulating hormone) as part of the initial laboratory workup for reproductive‑aged women presenting with abnormal uterine bleeding to exclude hyperprolactinemia and thyroid dysfunction as causes of anovulation. 4

Clinical Rationale

• Hyperprolactinemia is identified as a recognized endocrine cause of anovulation, which is a common mechanism underlying abnormal uterine bleeding; therefore, prolactin assessment is essential in the diagnostic algorithm. 4
• The PALM‑COEIN classification system categorizes ovulatory dysfunction as a non‑structural cause of abnormal uterine bleeding, mandating endocrine evaluation—including prolactin testing—to fully assess this category. 4

Management Implications

• Detecting hyperprolactinemia can fundamentally alter treatment strategy: addressing the underlying prolactin disorder may resolve bleeding without the need for hormonal contraception or surgical intervention. 4

Testing Pitfalls to Avoid

• Endocrine testing (prolactin and TSH) should not be omitted even when imaging suggests structural pathology, because co‑existing endocrine etiologies such as hyperprolactinemia require specific therapy distinct from standard bleeding management. 4

Chronic Anovulation: Diagnosis and Management

Epidemiology & Risk Factors

• Polycystic ovary syndrome (PCOS) affects approximately 4–6 % of women of reproductive age and is the leading cause of anovulatory infertility【5】.
• Obesity and diabetes are well‑established risk factors that predispose to chronic anovulation and PCOS【5】.

Clinical Presentation

• Irregular menstrual cycles occurring every 3–4 months are a hallmark sign of anovulatory bleeding, distinguishing it from normal ovulatory cycles【6】.
• Prolonged heavy menstrual bleeding with large clots reflects anovulatory dysfunctional uterine bleeding caused by unopposed estrogen–driven endometrial proliferation【6】.

Pathophysiology

• Excess adipose tissue increases peripheral aromatization of androgens to estrogen, resulting in chronic unopposed estrogen stimulation of the endometrium【6】.
• This hormonal milieu leads to continuous endometrial proliferation without progesterone‑mediated stabilization, producing irregular breakdown and unpredictable heavy bleeding【6】.
• Persistent unopposed estrogen exposure markedly raises the risk of endometrial hyperplasia and endometrial cancer in women with chronic anovulation【6】.

Diagnostic Recommendations

• Endometrial sampling (biopsy) is indicated for women with chronic anovulation who have obesity and diabetes, even if they are younger than 35 years, because of the heightened cancer risk【6】.
• Laboratory evaluation should include thyroid‑stimulating hormone (TSH) and prolactin levels to exclude thyroid dysfunction and hyperprolactinemia as alternative causes of anovulation【6】.

Management Considerations

• Prior to initiating hormonal therapy, clinicians must exclude endometrial hyperplasia or malignancy through tissue diagnosis, given the synergistic risk conferred by obesity, diabetes, and chronic anovulation【6】.

Chronic Anovulation: Evidence‑Based Summary

Diagnosis

• In individuals with obesity and diabetes who experience menstrual cycles occurring only every 3–4 months together with prolonged heavy bleeding, chronic anovulation is the most likely diagnosis. 7

Differential Diagnosis

• Fibroids usually cause heavy menstrual bleeding but occur in the setting of regular cycles; therefore they are less likely when cycles are markedly oligomenorrheic. 7
• Primary bleeding disorders typically produce heavy bleeding from menarche onward and affect all bleeding episodes (including minor trauma), not just menstrual bleeding with oligomenorrhea; thus they are unlikely in this presentation. 7
• Incomplete abortion can be ruled out when a negative pregnancy test is present and the pattern of irregular cycles predates the current bleeding episode. 8

Pathophysiology / Classification

• The PALM‑COEIN system classifies ovulatory dysfunction (the “O” category) as a non‑structural cause of abnormal uterine bleeding, commonly associated with heavy and irregular bleeding. [7][9]

Recommended Evaluation

Endometrial Assessment

• Endometrial sampling (biopsy) is advised for patients with obesity, diabetes, and chronic anovulation because the combination markedly raises the risk of endometrial hyperplasia and carcinoma from persistent unopposed estrogen exposure. 7

Hormonal Work‑up

• Serum thyroid‑stimulating hormone (TSH) and prolactin levels should be obtained to exclude thyroid dysfunction and hyperprolactinemia as alternative etiologies of anovulation. 7

Imaging

• Transvaginal ultrasound is recommended to measure endometrial thickness and to rule out structural lesions such as fibroids or polyps. [7][10]

Effectiveness of Progestin‑Only Contraception for Anovulatory Bleeding in Adolescents

Clinical Efficacy and Safety

• In adolescent females with anovulatory dysfunctional uterine bleeding, progestin‑only contraception—including the levonorgestrel‑releasing intrauterine device—is highly effective for controlling menstrual bleeding, although it may be associated with irregular bleeding patterns. 11 (Evidence level not specified)